Advertisement

Metabolically Healthy Obesity and Bariatric Surgery

  • Adriana Florinela CătoiEmail author
  • Luca Busetto
Review Article
  • 107 Downloads

Abstract

A peculiar category of persons with obesity lacking common metabolic disturbances has been depicted and termed as metabolically healthy obesity (MHO). Yet, although MHO patients are free of obesity-associated complications, they might not be entirely precluded from developing cardio-metabolic disorders. Among patients with morbid obesity (MO) who are referred to bariatric surgery, a subset of metabolically healthy MO (MHMO) has been identified and the question arises if these patients would benefit from surgery in terms of mitigating the peril of cardio-metabolic complications. We revisited the pathophysiological mechanisms that define MHO, the currently available data on the cardio-metabolic risk of these patients and finally we reviewed the benefits of bariatric surgery and the urge to better characterize MHMO before submission to surgery.

Keywords

Metabolically healthy obesity Morbid obesity Bariatric surgery 

Notes

Compliance with Ethical Standards

Ethical Approval Statement

This article does not contain any studies with human participants or animals performed by any of the authors.

References

  1. 1.
    Gonçalves CG, Glade MJ, Meguid MM. Metabolically healthy obese individuals: key protective factors. Nutrition. 2016;32(1):14–20.CrossRefPubMedGoogle Scholar
  2. 2.
    Grundy SM. Metabolic syndrome update. Trends Cardiovasc Med. 2016;26(4):364–73.CrossRefPubMedGoogle Scholar
  3. 3.
    Primeau V, Coderre L, Karelis AD, et al. Characterizing the profile of obese patients who are metabolically healthy. Int J Obes. 2011;35:971–81.CrossRefGoogle Scholar
  4. 4.
    Blüher M. Are metabolically healthy obese individuals really healthy? Eur Endocrinol. 2014;171(6):R209–19.CrossRefGoogle Scholar
  5. 5.
    Stefan N, Häring HU, Hu FB, et al. Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 2013;1:152–62.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Jung CH, Lee WJ, Song KH. Metabolically healthy obesity: a friend or foe? Korean J Intern Med. 2017;32:611–21.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kramer CK, Zinma B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? Ann Intern Med. 2013;159:758–69.CrossRefPubMedGoogle Scholar
  8. 8.
    Stefan N, Häring HU, Schulze MB. Metabolically healthy obesity: the low-hanging fruit in obesity treatment? Lancet Diabetes Endocrinol. 2018;6(3):249–58.CrossRefPubMedGoogle Scholar
  9. 9.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefPubMedGoogle Scholar
  10. 10.
    Heneghan HM, Nissen S, Schauer PR. Gastrointestinal surgery for obesity and diabetes: weight loss and control of hyperglycemia. Curr Atheroscler Rep. 2012;14(6):579–87.CrossRefPubMedGoogle Scholar
  11. 11.
    Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539–53.CrossRefPubMedGoogle Scholar
  12. 12.
    National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143–3421.Google Scholar
  13. 13.
    Grundy SM, Brewer Jr HB, Cleeman JI, et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13–8.PubMedGoogle Scholar
  14. 14.
    Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1059–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome :a joint interim statement of the International Diabetes Federation Task Force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1–16.CrossRefPubMedGoogle Scholar
  17. 17.
    Soares MJ, Pannu PK, Calton EK, et al. Vitamin D status and calcium intake in systemic inflammation, insulin resistance and the metabolic syndrome: an update on current evidence. Trends Food Sci Technol. 2017;62:79–90.CrossRefGoogle Scholar
  18. 18.
    Brochu M, Tchernof A, Dionne IJ, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86(3):1020–5.PubMedGoogle Scholar
  19. 19.
    Sims EA. Are there persons who are obese, but metabolically healthy? Metabolism. 2001;50(12):1499–504.CrossRefPubMedGoogle Scholar
  20. 20.
    Karelis A, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004;30:569–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999–2004). Arch Intern Med. 2008;168:1617–24.CrossRefGoogle Scholar
  22. 22.
    Aguilar-Salinas CA, Garcia EG, Robles L, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008;93:4075–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Meigs JB, Wilson PWF, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91:2906–12.CrossRefGoogle Scholar
  24. 24.
    Plourde G, Karelis AD. Current issues in the identification and treatment of metabolically healthy but obese individuals. Nutr Metab Cardiovasc Dis. 2014;24(5):455–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752–70.CrossRefPubMedGoogle Scholar
  26. 26.
    Velho S, Paccaud F, Waeber G, et al. Metabolically healthy obesity: different prevalences using different criteria. Eur J Clin Nutr. 2010;64:1043e51.CrossRefGoogle Scholar
  27. 27.
    van Vliet Ostaptchouk JV, Nuotio ML, Slagter SN, et al. The prevalence of metabolic syndrome and metabolically healthy obesity in Europe: a collaborative analysis of ten large cohort studies. BMC Endocr Disord. 2014;14:9.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Goday A, Benaiges D, Parri A, et al. Can bariatric surgery improve cardiovascular risk factors in the metabolically healthy but morbidly obese patient? Surg Obes Relat Dis. 2014;10:871–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Pelascini E, Disse E, Pasquer A, et al. Should we wait for metabolic complications before operating on obese patients? Gastric bypass outcomes in metabolically healthy obese individuals. Surg Obes Relat Dis. 2016;12:49–56.CrossRefPubMedGoogle Scholar
  30. 30.
    Lee CJ, Clark JM, Asamoah V, et al. Prevalence and characteristics of individuals without diabetes and hypertension who underwent bariatric surgery: lessons learned about metabolically healthy obese. Surg Obes Relat Dis. 2015;11(1):142–6.CrossRefPubMedGoogle Scholar
  31. 31.
    Haskins IN, Chang J, Nor Hanipah Z, et al. Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease? Surg Obes Relat Dis. 2018;14:342–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Grundy SM. Over nutrition, ectopic lipid and the metabolic syndrome. Investig Med. 2016;64:1082–6.CrossRefGoogle Scholar
  33. 33.
    Grundy SM. Adipose tissue and metabolic syndrome: too much, too little or neither. Eur J Clin Investig. 2015;45(11):1209–17.CrossRefGoogle Scholar
  34. 34.
    Blüher S, Schwarz P. Metabolically healthy obesity from childhood to adulthood—does weight status alone matter? Metabolism. 2014;63:1084–92.CrossRefPubMedGoogle Scholar
  35. 35.
    Antonopoulos AS, Tousoulis D. The molecular mechanisms of obesity paradox. Cardiovasc Res. 2017;113:1074–86.CrossRefPubMedGoogle Scholar
  36. 36.
    Baglioni S, Cantini G, Poli G, et al. Functional differences in visceral and subcutaneous fat pads originate from differences in the adipose stem cell. PLoS One. 2012;7:e36569.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Zeve D, Tang W, Graff J. Fighting fat with fat: the expanding field of adipose stem cells. Cell Stem Cell. 2009;5:472–81.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Blüher M. Adipose tissue dysfunction contributes to obesity related metabolic diseases. Best Pract Res Clin Endocrinol Metab. 2013;27(2):163–77.CrossRefPubMedGoogle Scholar
  39. 39.
    Tan CY, Vidal-Puig A. Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem Soc Trans. 2008;36:935–40.CrossRefPubMedGoogle Scholar
  40. 40.
    Smith U, Kahn BB. Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J Intern Med. 2016;280(5):465–75.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Blüher M. The distinction of metabolically ‘healthy’ from ‘unhealthy’ obese individuals. Curr Opin Lipidol. 2010;21(1):38–43.CrossRefPubMedGoogle Scholar
  42. 42.
    Klöting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299:E506–15.CrossRefPubMedGoogle Scholar
  43. 43.
    O’Connell J, Lynch L, Cawood TJ, et al. The relationship of omental and subcutaneous adipocyte size to metabolic disease in severe obesity. PLoS One. 2010;5:e9997.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    McLaughlin T, Sherman A, Tsao P, et al. Enhanced proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese individuals implicates impaired adipogenesis. Diabetologia. 2007;50:1707–15.CrossRefPubMedGoogle Scholar
  45. 45.
    Alligier M, Gabert L, Meugnier E, et al. Visceral fat accumulation during lipid overfeeding is related to subcutaneous adipose tissue characteristics in healthy men. J Clin Endocrinol Metab. 2013;98:802–10.CrossRefPubMedGoogle Scholar
  46. 46.
    Isakson P, Hammarstedt A, Gustafson B, et al. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes. 2009;58:1550–7.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Crewe C, An YA, Scherer PE. The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis. J Clin Invest. 2017;127:74–82.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    O’Rourke RW. Molecular mechanisms of obesity and diabetes: at the intersection of weight regulation, inflammation, and glucose homeostasis. World J Surg. 2009;33:2007–13.CrossRefPubMedGoogle Scholar
  49. 49.
    Badoud F, Perreault M, Zulyniak MA, et al. Molecular insights into the role of white adipose tissue in metabolically unhealthy normal weight and metabolically healthy obese individuals. FASEB J. 2015;29:748–58.CrossRefPubMedGoogle Scholar
  50. 50.
    Hoffstedt J, Arner E, Wahrenberg H, et al. Regional impact of adipose tissue morphology on the metabolic profile in morbid obesity. Diabetologia. 2010;53(12):2496–503.CrossRefPubMedGoogle Scholar
  51. 51.
    McLaughlin T, Lamendola C, Coghlan N, et al. Subcutaneous adipose cell size and distribution: relationship to insulin resistance and body fat. Obesity (Silver Spring). 2014;22:673–80.CrossRefGoogle Scholar
  52. 52.
    Stefan N, Kantartzis K, Machann J, et al. Identification and characterization of metabolically benign obesity in humans. Arch Intern Med. 2008;168(15):1609–16.CrossRefGoogle Scholar
  53. 53.
    Macotela Y, Emanuelli B, Mori MA, et al. Intrinsic differences in adipocyte precursor cells from different white fat depots. Diabetes. 2012;61:1691–9.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Danforth Jr E. Failure of adipocyte differentiation causes type II diabetes mellitus? Nat Genet. 2000;26(1):13.CrossRefPubMedGoogle Scholar
  55. 55.
    Lee MJ, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity. Compl Mol Asp Med. 2013;34(1):1–11.CrossRefGoogle Scholar
  56. 56.
    Mathew H, Farr OM, Mantzoros CS. Metabolic health and weight: understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism. 2016;65(1):73–80.CrossRefPubMedGoogle Scholar
  57. 57.
    Fox CS, Massaro JM, Hoffmann U, et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation. 2007;116:39–48.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Abraham TM, Pedley A, Massaro JM, et al. Association between visceral and subcutaneous adipose depots and incident cardiovascular disease risk factors. Circulation. 2015;132(17):1639–47.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Sattar N, Gill JM. Type 2 diabetes as a disease of ectopic fat? BMC Med. 2014;12:123.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Pardina E, Ferrer R, Rossell J, et al. Diabetic and dyslipidaemic morbidly obese exhibit more liver alterations compared with healthy morbidly obese. BBA Clin. 2016;5:54–65.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90(7):4145–50.CrossRefPubMedGoogle Scholar
  62. 62.
    Matsuzawa Y, Funahashi T, Nakamura T. The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. J Atheroscler Thromb. 2011;18:629–39.CrossRefPubMedGoogle Scholar
  63. 63.
    Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93:359–404.CrossRefPubMedGoogle Scholar
  64. 64.
    Messier V, Karelis AD, Prud’homme D, et al. Identifying metabolically healthy but obese individuals in sedentary postmenopausal women. Obesity. 2010;18:911–7.CrossRefGoogle Scholar
  65. 65.
    Martínez-Larrad MT, Corbatón Anchuelo A, Del Prado N, et al. Profile of individuals who are metabolically healthy obese using different definition criteria. A population-based analysis in the Spanish population. PLoS One. 2014;9(9):e106641.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Alfadda AA, Masood A, Al-Naami MY, et al. A proteomics based approach reveals differential regulation of visceral adipose tissue proteins between metabolically healthy and unhealthy obese patients. Mol Cells. 2017;40(9):685–95.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Nazare JA, Smith JD, Borel AL, et al. Ethnic influences on the relations between abdominal subcutaneous and visceral adiposity, liver fat, and cardiometabolic risk profile: the international study of prediction of intra-abdominal adiposity and its relationship with cardiometabolic risk/intra-abdominal adiposity. Am J Clin Nutr. 2012;96:714–26.CrossRefPubMedGoogle Scholar
  68. 68.
    Kabir M, Catalano KJ, Ananthnarayan S, et al. Molecular evidence supporting the portal theory: a causative link between visceral adiposity and hepatic insulin resistance. Am J Physiol Endocrinol Metab. 2005;288(2):E454–61.CrossRefPubMedGoogle Scholar
  69. 69.
    Mathieu P, Boulanger MC, Després JP. Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk. Rev Endocr Metab Disord. 2014;15:289–98.CrossRefPubMedGoogle Scholar
  70. 70.
    Tinahones FJ, Garrido-Sanchez L, Miranda M, et al. Obesity and insulin resistance-related changes in the expression of lipogenic and lipolytic genes in morbidly obese subjects. Obes Surg. 2010;20:1559–67.CrossRefPubMedGoogle Scholar
  71. 71.
    Messier V, Karelis AD, Robillard ME, et al. Metabolically healthy but obese individuals: relationship with hepatic enzymes. Metabolism. 2010;59:20–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Ogorodnikova AD, Khan UI, McGinn AP, et al. Ectopic fat and adipokines in metabolically benign overweight/ obese women: the Kronos Early Estrogen Prevention Study. Obesity (Silver Spring). 2013;21:1726–33.CrossRefGoogle Scholar
  73. 73.
    Faria G, Gonçalves A, Cunha R, et al. Beyond central adiposity: liver fat and visceral fat area are associated with metabolic syndrome in morbidly obese patients. Int J Surg. 2015 Feb;14:75–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697–738.CrossRefPubMedGoogle Scholar
  75. 75.
    Gesta S, Blüher M, Yamamoto Y, et al. Evidence for a role of developmental genes in the origin of obesity and body fat distribution. Proc Natl Acad Sci U S A. 2006;103:6676–81.CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Yaghootkar H, Scott RA, White CC, et al. Genetic evidence for a normal-weight “metabolically obese” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes. 2014;63(12):4369–77.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Scott RA, Lagou V, Welch RP, et al. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet. 2012;44:991–1005.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Manning AK, Hivert MF, Scott RA, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet. 2012;44:659–69.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Lotta LA, Gulati P, Day FR, et al. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat Genet. 2017;49:17–26.CrossRefPubMedGoogle Scholar
  80. 80.
    Trayhurn P, Wang B, Wood IS. Hypoxia and the endocrine and signalling role of white adipose tissue. Arch Physiol Biochem. 2008;114(4):267–76.CrossRefPubMedGoogle Scholar
  81. 81.
    Bondia-Pons I, Ryan L, Martinez JA. Oxidative stress and inflammation interactions in human obesity. J Physiol Biochem. 2012;68(4):701–11.CrossRefPubMedGoogle Scholar
  82. 82.
    Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. JClin Invest. 2003;112:1796–808.CrossRefGoogle Scholar
  83. 83.
    Cancello R, Tordjman J, Poitou C, et al. Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes. 2006;55:1554–61.CrossRefPubMedGoogle Scholar
  84. 84.
    Harman-Boehm I, Bluher M, Redel H, et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J Clin Endocrinol Metab. 2007;92:2240–7.CrossRefPubMedGoogle Scholar
  85. 85.
    Vohl MC, Sladek R, Robitaille J, et al. A survey of genes differentially expressed in subcutaneous and visceral adipose tissue in men. Obes Res. 2004;12(8):1217–22.CrossRefPubMedGoogle Scholar
  86. 86.
    Cinti S, Mitchell G, Barbatelli G, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. J Lipid Res. 2005;46(11):2347–55.CrossRefPubMedGoogle Scholar
  87. 87.
    Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98:E1610–9.CrossRefGoogle Scholar
  88. 88.
    Koster A, Stenholm S, Alley DE, et al. Body fat distribution and inflammation among obese older adults with and without metabolic syndrome. Obesity (Silver Spring). 2010;18:2354–61.CrossRefGoogle Scholar
  89. 89.
    Shin MJ, Hyun YJ, Kim OY, et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes. 2006;30:1529–34.CrossRefGoogle Scholar
  90. 90.
    Wildman RP, Kaplan R, Manson JE, et al. Body size phenotypes and inflammation in the Women’s Health Initiative Observational Study. Obesity (Silver Spring). 2011;19:1482–149.CrossRefGoogle Scholar
  91. 91.
    Gómez-Ambrosi J, Catalán V, Rodríguez A, et al. Increased cardiometabolic risk factors and inflammation in adipose tissue in obese subjects classified as metabolically healthy. Diabetes Care. 2014;37(10):2813–21.CrossRefGoogle Scholar
  92. 92.
    Iglesias Molli AE, Penas Steinhardt A, López AP, et al. Metabolically healthy obese individuals present similar chronic inflammation level but less insulin-resistance than obese individuals with metabolic syndrome. PLoS One. 2017;12(12):e0190528.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Olefsky JM, Glass CK. Macrophages, inflammation and insulin resistance. Annu Rev Physiol. 2010;72:219–46.CrossRefPubMedGoogle Scholar
  94. 94.
    Jiménez A, Perea V, Corcelles R, et al. Metabolic effects of bariatric surgery in insulin-sensitive morbidly obese subjects. Obes Surg. 2013;23(4):494–500.CrossRefPubMedGoogle Scholar
  95. 95.
    Soverini V, Moscatiello S, Villanova N, et al. Metabolic syndrome and insulin resistance in subjects with morbid obesity. Obes Surg. 2010;20(3):295–301.CrossRefPubMedGoogle Scholar
  96. 96.
    Cătoi AF, Pârvu AE, Andreicuț AD, et al. Metabolically healthy versus unhealthy morbidly obese: chronic inflammation, nitro-oxidative stress, and insulin resistance. Nutrients. 2018;10:1199.CrossRefGoogle Scholar
  97. 97.
    Marques-Vidal P, Velho S, Waterworth D, et al. The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used. Eur J Clin Nutr. 2012;66:426–35.CrossRefGoogle Scholar
  98. 98.
    Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836–43.CrossRefPubMedGoogle Scholar
  99. 99.
    Barbarroja N, López-Pedrera R, Mayas MD, et al. The obese healthy paradox: is inflammation the answer? Biochem J. 2010;430(1):141–9.CrossRefPubMedGoogle Scholar
  100. 100.
    van Beek L, Lips MA, Visser A, et al. Increased systemic and adipose tissue inflammation differentiates obese women with T2DM from obese women with normal glucose tolerance. Metabolism. 2014;63(4):492–501.CrossRefPubMedGoogle Scholar
  101. 101.
    Doumatey AP, Zhou J, Zhou M, et al. Proinflammatory and lipid biomarkers mediate metabolically healthy obesity: a proteomics study. Obesity. 2016;24(6):1257–65.CrossRefPubMedGoogle Scholar
  102. 102.
    Hinnouho GM, Czernichow S, Dugravot A, et al. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur Heart J. 2015;36:551–9.CrossRefPubMedGoogle Scholar
  103. 103.
    Kim TJ, Shin HY, Chang Y, et al. Metabolically healthy obesity and the risk for subclinical atherosclerosis. Atherosclerosis. 2017;262:191–7.CrossRefPubMedGoogle Scholar
  104. 104.
    Mongraw-Chaffin M, Foster MC, Kalyani RR, et al. Obesity severity and duration are associated with incident metabolic syndrome: evidence against metabolically healthy obesity from the Multi-Ethnic Study of Atherosclerosis. J Clin Endocrinol Metab. 2016;101:4117–24.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Appelton. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype. Diabetes Care. 2013;36:2388–94.CrossRefGoogle Scholar
  106. 106.
    Soriguer F, Gutierrez-Repiso C, Rubio-Martin E, et al. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J Clin Endocrinol Metab. 2013;98:2318–25.CrossRefPubMedGoogle Scholar
  107. 107.
    Hamer M, Bell JA, Sabia S, et al. Stability of metabolically healthy obesity over 8 years: the English Longitudinal Study of Ageing. Eur J Endocrinol. 2015;173:703–8.CrossRefPubMedGoogle Scholar
  108. 108.
    Eshtiaghi R, Keihani S, Hosseinpanah F, et al. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: the Tehran Lipid and Glucose Study. Int J Obes. 2015;39:514–9.CrossRefGoogle Scholar
  109. 109.
    Ortega FB, Lee DC, Katzmarzyk PT, et al. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur Heart J. 2013;34:389–97.CrossRefPubMedGoogle Scholar
  110. 110.
    Garcia-Moll X. Obesity and prognosis: time to forget about metabolically healthy obesity. Eur Heart J. 2018;39(5):407–9.CrossRefPubMedGoogle Scholar
  111. 111.
    Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European Society of Cardiology and Other Societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37:2315–81.CrossRefPubMedPubMedCentralGoogle Scholar
  112. 112.
    Lassale C, Tzoulaki I, Moons KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur J Cardiol Eur Heart J. 2018;39(5):397–406.CrossRefGoogle Scholar
  113. 113.
    Moussa O, Arhi C, Ziprin P, et al. Fate of the metabolically healthy obese—is this term a misnomer? A study from the Clinical Practice Research Datalink. Int J Obes. 2018;43:1093–101.  https://doi.org/10.1038/s41366-018-0096-z.CrossRefGoogle Scholar
  114. 114.
    Eckel N, Li Y, Kuxhaus O, et al. Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses’ Health Study): 30 year follow-up from a prospective cohort study. Lancet Diabetes Endocrinol. 2018;6(9):714–24.CrossRefPubMedGoogle Scholar
  115. 115.
    Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann Intern Med. 2013;159:758–69.CrossRefPubMedGoogle Scholar
  116. 116.
    Caleyachetty R, Thomas N, Toulis KA, et al. Metabolically healthy obese and incident cardiovascular disease events among 3·5 million men and women. J Am Coll Cardiol. 2017;70:1429–37.CrossRefPubMedGoogle Scholar
  117. 117.
    Eckel N, Meidtner K, Kalle-Uhlmann T, et al. Metabolically healthy obesity and cardiovascular events: a systematic review and meta-analysis. Eur J Prev Cardiol. 2016;23:956–66.CrossRefPubMedGoogle Scholar
  118. 118.
    Mongraw-Chaffin M, Foster MC, Anderson CAM, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71:1857–65.CrossRefPubMedPubMedCentralGoogle Scholar
  119. 119.
    Bradshaw PT, Reynolds KR, Wagenknecht LE, et al. Incidence of components of metabolic syndrome in the metabolically healthy obese over 9 years follow-up: the Atherosclerosis Risk In Communities study. Int J Obes. 2018;42:295–301.CrossRefGoogle Scholar
  120. 120.
    Jung CH, Lee MJ, Kang YM, et al. The risk of incident type 2 diabetes in a Korean metabolically healthy obese population: the role of systemic inflammation. J Clin Endocrinol Metab. 2015;100(3):934–41.CrossRefPubMedGoogle Scholar
  121. 121.
    Achilike I, Hazuda HP, Fowler SP, et al. Predicting the development of the metabolically healthy obese phenotype. Int J Obes. 2015;39(2):228–34.CrossRefGoogle Scholar
  122. 122.
    Ricci C, Gaeta M, Rausa E, et al. Long-term effects of bariatric surgery on type II diabetes, hypertension and hyperlipidemia: a meta-analysis and meta-regression study with 5-year follow-up. Obes Surg. 2015;25(3):397–405.CrossRefPubMedGoogle Scholar
  123. 123.
    Benaiges D, Flores Le-Roux JA, Pedro-Botet J, et al. Sleeve gastrectomy and Roux-en-Y gastric bypass are equally effective in correcting insulin resistance. Int J Surg. 2013;11:309–13.CrossRefPubMedGoogle Scholar
  124. 124.
    Benaiges D, Flores JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery procedure (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22:1268–75.CrossRefPubMedGoogle Scholar
  125. 125.
    Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–93.CrossRefPubMedGoogle Scholar
  126. 126.
    Sesti G, Folli F, Perego L, et al. Effects of weight loss in metabolically healthy obese subjects after laparoscopic adjustable gastric banding and hypocaloric diet. PLoS One. 2011;6:e17737.CrossRefPubMedPubMedCentralGoogle Scholar
  127. 127.
    Moreno-Castellanos N, Guzmán-Ruiz R, Cano DA, et al. The effects of bariatric surgery-induced weight loss on adipose tissue in morbidly obese women depends on the initial metabolic status. Obes Surg. 2016;26(8):1757–67.CrossRefPubMedGoogle Scholar
  128. 128.
    Sjostrom L. Review of the key results from the Swedish Obese Subjects (SOS) trial—a prospective controlled intervention study of bariatric surgery. J Intern Med. 2013;273(3):219–34.CrossRefPubMedGoogle Scholar
  129. 129.
    Ferrer R, Pardina E, Rossell J, et al. Morbidly “healthy” obese are not metabolically healthy but less metabolically imbalanced than those with type 2 diabetes or dyslipidemia. Obes Surg. 2015;25(8):1380–91.CrossRefPubMedGoogle Scholar
  130. 130.
    Busetto L. Timing of bariatric surgery in people with obesity and diabetes. Ann Transl Med. 2015;3(7):94.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Pathophysiology Department, Faculty of Medicine, ‘Iuliu Hațieganu’University of Medicine and Pharmacy Cluj-Napoca RomaniaCluj-NapocaRomania
  2. 2.Department of MedicineUniversity of PadovaPaduaItaly

Personalised recommendations